

**Supplementary Table S4:** Relationship between confounding factors and response (RECIST)

Potential Confounders	Levels	MBC		mCRPC		Total	
		PD ( <i>n</i> ), SD ( <i>n</i> )	<i>P</i> -value <sup>a</sup>	PD ( <i>n</i> ), SD ( <i>n</i> )	<i>P</i> -value <sup>a</sup>	PD ( <i>n</i> ), SD ( <i>n</i> )	<i>P</i> -value <sup>a</sup>
Dose level	1 mg/kg	5, 0	0.149	3, 0	0.143	8, 0	0.006
	1.25mg/kg	2, 3		1, 3		3, 6	
	100 mg	9, 2		0, 0		9, 2	
Age	<65	12, 4	1	1, 2	0.486	13, 6	1
	≥65	4, 1		3, 1		7, 2	
Gender	Female	15, 4	0.429	0, 0	1	15, 4	0.371
	Male	1, 1		4, 3		5, 4	
Site	101	11, 5	0.278	4, 3	1	15, 8	0.281
	102	5, 0		0, 0		5, 0	

<sup>a</sup>Fisher exactAbbreviations: MBC, metastatic breast cancer; mCRPC, metastatic castration-resistant prostate cancer; *n*, number of evaluable samples; PD, progressive disease; SD, stable disease.